tbuckley/cabot-search huggingface dataset:
Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study
Authors: Irene Cassaniti, Federica Bergami, Elena Percivalle, Elisa Gabanti, Josè Camilla Sammartino, Alessandro Ferrari, Kodjo Messan Guy Adzasehoun, Federica Zavaglio, Paola Zelini, Giuditta Comolli, Antonella Sarasini, Antonio Piralla, Alessandra Ricciardi, Valentina Zuccaro, Fabrizio Maggi, Federica Novazzi, Luca Simonelli, Luca Varani, Daniele Lilleri, Fausto Baldanti
Journal: Clinical Microbiology and Infection (2021)

To assess the humoral and cell-mediated response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicited by the mRNA BNT162b2 vaccine in SARS-CoV-2-experienced and -naive subjects against a reference strain and SARS-CoV-2 variants.The humoral response (including neutralizing antibodies) and T-cell-mediated response elicited by BNT162b2 vaccine in 145 healthcare workers (both naive and positive for previous SARS-CoV-2 infection) were evaluated. In a subset of subjects, the effect of SARS-CoV-2 variants on antibody level and cell-mediated response was also investigated.Overall, 125/127 naive subjects (98.4%) developed both neutralizing antibodies and specific T cells after the second dose of vaccine. Moreover, the antibody and T-cell responses were effective against viral variants since SARS-CoV-2 NT Abs were still detectable in 55/68 (80.9%) and 25/29 (86.2%) naive subjects when sera were challenged against β and δ variants, respectively. T-cell response was less affected, with no significant difference in the frequency of responders (p 0.369). Of note, two doses of vaccine were able to elicit sustained neutralizing antibody activity against all the SARS-CoV-2 variants tested in SARS-CoV-2-experienced subjects.BNT162b2 vaccine elicited a sustained humoral and cell-mediated response in immunocompetent subjects after two-dose administration of the vaccine, and the response seemed to be less affected by SARS-CoV-2 variants, the only exceptions being the β and δ variants. Increased immunogenicity, also against SARS-CoV-2 variant strains, was observed in SARS-CoV-2-experienced subjects. These results suggest that triple exposure to SARS-CoV-2 antigens might be proposed as valuable strategy for vaccination campaigns.
540P Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8α co-receptor and an affinity optimized TCR targeting MAGE-A4
Authors: D.S. Hong, J.M. Clarke, A. Asch, J. Charlson, T.M. Johanns, E. Calvo, V. Boni, M.J. de Miguel, V. Moreno Garcia, D.P. Lawrence, M.O. Butler, J. Zugazagoitia, M.A. Blum Murphy, P. Kebriaei, G.R. Blumenschein, Q. Lin, H. Danesi, E. Norry
Journal: Annals of Oncology (2021)
CXCR6 by increasing retention of memory CD8<sup>+</sup> T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer
Authors: Ravikumar Muthuswamy, AJ Robert McGray, Sebastiano Battaglia, Wenjun He, Anthony Miliotto, Cheryl Eppolito, Junko Matsuzaki, Tsuji Takemasa, Richard Koya, Thinle Chodon, Brian D Lichty, Protul Shrikant, Kunle Odunsi
Journal: Journal for ImmunoTherapy of Cancer (2021)

Resident memory CD8 T cells, owing to their ability to reside and persist in peripheral tissues, impart adaptive sentinel activity and amplify local immune response, and have beneficial implications for tumor surveillance and control. The current study aimed to clarify the less known chemotactic mechanisms that govern the localization, retention, and residency of memory CD8 T cells in the ovarian tumor microenvironment.RNA and protein expressions of chemokine receptors in CD8+ resident memory T cells in human ovarian tumor-infiltrating CD8+ T cells and their association with survival were analyzed. The role of CXCR6 on antitumor T cells was investigated using prophylactic vaccine models in murine ovarian cancer.Chemokine receptor profiling of CD8+CD103+ resident memory tumor-infiltrating lymphocytes in patients with ovarian cancer revealed high expression of CXCR6. Analysis of The Cancer Genome Atlas (TCGA) (ovarian cancer database revealed CXCR6 to be associated with CD103 and increased patient survival. Functional studies in mouse models of ovarian cancer revealed that CXCR6 is a marker of resident, but not circulatory, tumor-specific memory CD8+ T cells. CXCR6-deficient tumor-specific CD8+ T cells showed reduced retention in tumor tissues, leading to diminished resident memory responses and poor control of ovarian cancer.CXCR6, by promoting retention in tumor tissues, serves a critical role in resident memory T cell-mediated immunosurveillance and control of ovarian cancer. Future studies warrant exploiting CXCR6 to promote resident memory responses in cancers.
535P Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer
Authors: M.S. Brose, L. Shen, D.S.W. Tan, S. Kummar, J.J. Lin, R. McDermott, J. Berlin, M. Tahara, U.N. Lassen, S. Leyvraz, J.D. Patel, R. Norenberg, L. Dima, N. Brega, D.S. Hong, A. Drilon
Journal: Annals of Oncology (2021)
Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy
Authors: Alejandro Ibáñez-Costa, Carlos Perez-Sanchez, Alejandra María Patiño-Trives, Maria Luque-Tevar, Pilar Font, Ivan Arias de la Rosa, Cristobal Roman-Rodriguez, Mª Carmen Abalos-Aguilera, Carmen Conde, Antonio Gonzalez, Sergio Pedraza-Arevalo, Mercedes del Rio-Moreno, Ricardo Blazquez-Encinas, Pedro Segui, Jerusalem Calvo, Rafaela Ortega Castro, Alejandro Escudero-Contreras, Nuria Barbarroja, Mª Angeles Aguirre, Justo P Castaño, Raul M Luque, Eduardo Collantes-Estevez, Chary Lopez-Pedrera
Journal: Annals of the Rheumatic Diseases (2021)

Objectives To characterise splicing machinery (SM) alterations in leucocytes of patients with rheumatoid arthritis (RA), and to assess its influence on their clinical profile and therapeutic response. Methods Leucocyte subtypes from 129 patients with RA and 29 healthy donors (HD) were purified, and 45 selected SM elements (SME) were evaluated by quantitative PCR-array based on microfluidic technology (Fluidigm). Modulation by anti-tumour necrosis factor (TNF) therapy and underlying regulatory mechanisms were assessed. Results An altered expression of several SME was found in RA leucocytes. Eight elements ( SNRNP70, SNRNP200, U2AF2, RNU4ATAC, RBM3, RBM17, KHDRBS1 and SRSF10 ) were equally altered in all leucocytes subtypes. Logistic regressions revealed that this signature might: discriminate RA and HD, and anti-citrullinated protein antibodies (ACPAs) positivity; classify high-disease activity (disease activity score-28 (DAS28) &gt;5.1); recognise radiological involvement; and identify patients showing atheroma plaques. Furthermore, this signature was altered in RA synovial fluid and ankle joints of K/BxN-arthritic mice. An available RNA-seq data set enabled to validate data and identified distinctive splicing events and splicing variants among patients with RA expressing high and low SME levels. 3 and 6 months anti-TNF therapy reversed their expression in parallel to the reduction of the inflammatory profile. In vitro, ACPAs modulated SME, at least partially, by Fc Receptor (FcR)-dependent mechanisms. Key inflammatory cytokines further altered SME. Lastly, induced SNRNP70- overexpression and KHDRBS1 -overexpression reversed inflammation in lymphocytes, NETosis in neutrophils and adhesion in RA monocytes and influenced activity of RA synovial fibroblasts. Conclusions Overall, we have characterised for the first time a signature comprising eight dysregulated SME in RA leucocytes from both peripheral blood and synovial fluid, linked to disease pathophysiology, modulated by ACPAs and reversed by anti-TNF therapy.
200TiP ELEANOR: A multi-national, prospective, non-interventional study (NIS) in patients with human epidermal growth factor receptor (HER2) positive, early breast cancer (eBC) observing real-life extended adjuvant treatment with neratinib and concurrent use of the eHealth solution CANKADO
Authors: N. Harbeck, D. Lüftner, U. Breitenstein, C. Jackisch, V. Müller, M. Schmidt, M. Balic, G. Rinnerthaler, M. Schwitter, K. Zaman, D. Wrobel, D. Guth, J. Terhaag, M. Zaiss, T. Schinköthe, R. Bartsch
Journal: Annals of Oncology (2021)
1695P ePRO follow-up of colorectal cancer patients receiving oxaliplatin-based adjuvant chemotherapy is feasible and enhances the quality of patient care
Authors: S.M.E. Iivanainen, R. Ravi, A. Jekunen, R. Arokoski, J. Ekstrom, S. Mentu, H. Virtanen, V. Kataja, J.P. Koivunen
Journal: Annals of Oncology (2021)
생체 부분 간이식후 1개월내 총빌리루빈 재상승 환자에서 Biliary Canalicular Transporter 유전자 mRNA 발현
Authors: 최종영, 조세현, 윤승규, 양진모, 한준열, 안병민, 이영석, 이창돈, 차상복, 정규원, 선희식, 김소연, 김동구
Journal: Clinical and Molecular Hepatology (2003)

배경/목적: 생체 부분 간이식 직후 특별한 합병증이 없는 경우, 혈청 트란스아미나제는 수술 후 급격하게 호전되며, 총빌리루빈은 1-2주 사이에 약 5mg/이 이하로 감소한다. 본 병원에서 경험한 일부 환자에서 2-3주경에 특별한 원인 없이 총빌리루빈이 5 mg/dl 이상 재상승 하였다. 수술에 연관된 합병증, 급성거부반응, 감염등이 감별되어 약제등 다른 원인을 생각하였다. 면역억제제중 사이클로스포린이 동물실험에서 담즙울체를 일으킨다고 알려져 있다. 이에 생체간이식후 담즙울체의 기전을 알아보기 위하여 간조직내 biliary canalicular transporter 유전자 발현을 연구하였다. 대상과 방법: 2001년에서 2003년 3월까지 성인 생체 부분 간이식을 받은 75명의 환자 중 이식 후 총빌리루빈이 감소하다가 이식후 2-3주 사이 주로 총빌리루빈이 5 mg/dl 이상 재상승하였던 16명(A군), 혈청트란스아미나제와 총빌리루빈이 동시에 증가한 5명(B군)에서 간세침 조직검사시 채취된 간조직 21예를 대상으로 하였다. 대조군으로 생체 간이식 공여자의 간조직 3예를 이용하였다. 남자 18 명, 여자가 3 명이었고, 평균 연령은 47 세 (범위 29-64) 였다. 수술직후 면역억제제로는 전 환자에서 사이클로스포린을 사용하였다. 냉동 보관된 간조직내에서 bile canalicular transporter 인 MDR1, MDR3, MRP2, MRP3, BSEP, NTCP을 mRNA 발현정도를 realtime RT-PCR을 이용하여 정량적으로 분석하였다. 파라핀 조직에서 MDR1의 단백질인 p-glycoprotein을 면역조직화학 염색하였고, 조직학적인 소견을 비교하였다. 결과: 간조직학적 검사에서 A군은 급성거부반응은 없거나 경미하면서, 주로 간세포내 담즙울체, 간세엽내 spotty necrosis 가 주로 관찰되었고, B군은 급성거부반응은 없고, 간문맥부위에 다핵형백혈구, bile canaliculi 에 담즙울체가 있어 bile 배출장애와 cholangitis 소견을 보였다. Bile canlicular transporter 유전자의 mRNA 정량검사 결과 BSEP, MRP2 발현은 A군에서 B군이나 정상간 에 비교해서 의미있게 감소되었다. MRP3 발현은 B군이 A군과 정상간 보다는 증가되었다. MDR1은 세그룹간에 차이가 없었고, MDR3, NTCP 유전자 발현은 A군이 정상보다는 발현이 증가되었다. p-glycoprotein 면역조직화학염색결과 정상조직에 비교해서 A군에서 발현이 증가되었다. 결론: 성인 생체 부분 간이식 후 1개월내 담즙울체는 bile canalicular transporter 유전자중 BSEP, MRP2, MRP3 발현감소와 연관이 있다. MDR3 유전자 발현증가는 담즙울체시 간세포내 축척된 독성물질을 배출하기 위해 보상기전으로 생각할 수 있다. 동물실험에서 사이클로스포린이 bile canalicular transporter 유전자 발현을 직접 혹은 간접적으로 영향을 미친다는 점에서 생체 부분 간이식 후 1개월내 총빌리루빈 재상승의 원인은 사이클로스포린과 관련이 있을 것으로 생각된다.
936P Effects of tislelizumab (TIS) monotherapy on health-related quality of life in patients with previously treated unresectable hepatocellular carcinoma (HCC)
Authors: Z. Ren, E. Assenat, L. Rimassa, W. Fang, B. Tang, S. Chica Duque, V. Li, J. Wu, Y. Wang, G. Barnes
Journal: Annals of Oncology (2021)
73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis
Authors: E. Yu, J.M. Piulats, G. Gravis, P. Fong, T. Todenhöfer, B. Laguerre, J. Arranz, S. Oudard, C. Massard, M. Stoeckle, L.T. Nordquist, J. Carles, M. Huang, Y. Li, P. Qiu, C.H. Poehlein, C. Schloss, J. de Bono
Journal: Annals of Oncology (2021)
Systems Biology of the Vasopressin V2 Receptor: New Tools for Discovery of Molecular Actions of a GPCR
Authors: Lihe Chen, Hyun Jun Jung, Arnab Datta, Euijung Park, Brian G. Poll, Hiroaki Kikuchi, Kirby T. Leo, Yash Mehta, Spencer Lewis, Syed J. Khundmiri, Shaza Khan, Chung-Lin Chou, Viswanathan Raghuram, Chin-Rang Yang, Mark A. Knepper
Journal: The Annual Review of Pharmacology and Toxicology (2021)

Systems biology can be defined as the study of a biological process in which all of the relevant components are investigated together in parallel to discover the mechanism. Although the approach is not new, it has come to the forefront as a result of genome sequencing projects completed in the first few years of the current century. It has elements of large-scale data acquisition (chiefly next-generation sequencing-based methods and protein mass spectrometry) and large-scale data analysis (big data integration and Bayesian modeling). Here we discuss these methodologies and show how they can be applied to understand the downstream effects of GPCR signaling, specifically looking at how the neurohypophyseal peptide hormone vasopressin, working through the V2 receptor and PKA activation, regulates the water channel aquaporin-2. The emerging picture provides a detailedframework for understanding the molecular mechanisms involved in water balance disorders, pointing the way to improved treatment of both polyuric disorders and water-retention disorders causing dilutional hyponatremia.
Loss of host tissue transglutaminase boosts antitumor T cell immunity by altering STAT1/STAT3 phosphorylation in ovarian cancer
Authors: Livia Elena Sima, Siqi Chen, Horacio Cardenas, Guangyuan Zhao, Yinu Wang, Cristina Ivan, Hao Huang, Bin Zhang, Daniela Matei
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Tissue transglutaminase (TG2), an enzyme overexpressed in cancer cells, promotes metastasis and resistance to chemotherapy. Its distinct effects in cancer versus the host compartments have not been elucidated. Methods Here, by using a TG2 -/- syngeneic ovarian cancer mouse model, we assessed the effects of TG2 deficiency in the host tissues on antitumor immunity and tumor progression. Multicolor flow cytometry was used to phenotype immune cell populations in the peritoneal environment. Cancer cells recovered from malignant ascites were characterized by RNA sequencing, proliferation, and apoptosis assays. Results We observed that host TG2 loss delayed tumor growth and ascites accumulation and caused increased infiltration of CD8 + T cells and decreased numbers of myeloid cells in the peritoneal fluid. Tumor antigen-specific CD8 + T cell cytotoxic responses were enhanced in ascites from TG2 -/- versus TG2 +/+ mice and CD8 + T cell depletion caused accelerated ascites accumulation in TG2 -/- mice. CD8 + T cells from tumor-bearing TG2 -/- mice displayed an effector T cell phenotype, differentiated toward effector memory (T em ). Mechanistically, absence of TG2 augmented signals promoting T cell activation, such as increased cytokine-induced STAT1 and attenuated STAT3 phosphorylation in T cells. Additionally, immune-suppressive myeloid cell populations were reduced in the peritoneal milieu of TG2 -/- tumor-bearing mice. In response to the more robust immune response caused by loss of TG2, cancer cells growing intraperitoneally exhibited an interferon-γ (IFN-γ) responsive gene signature and underwent apoptosis. In human specimens, stromal, not tumor, TG2 expression correlated indirectly with numbers of tumor-infiltrating lymphocytes. Conclusions Collectively, our data demonstrate decreased tumor burden, increased activation and effector function of T cells, and loss of immunosuppressive signals in the tumor microenvironment of TG2 -/- mice. We propose that TG2 acts as an attenuator of antitumor T cell immunity and is a new immunomodulatory target.
Effectiveness of a lifestyle weight-loss intervention targeting inactive former elite athletes: the Champ4Life randomised controlled trial
Authors: Analiza M Silva, Catarina L Nunes, Filipe Jesus, Ruben Francisco, Catarina N Matias, Miguel Cardoso, Inês Santos, Eliana V Carraça, Graham Finlayson, Marlene Nunes Silva, Stephanie Dickinson, David Allison, Cláudia S Minderico, Paulo Martins, Luis B Sardinha
Journal: British Journal of Sports Medicine (2021)

Objectives Many athletes struggle in managing the end of their career, often gaining weight and adopting unhealthy lifestyles. Lifestyle programmes targeting former athletes who have gained substantial fat mass (FM) postsports career are lacking. We studied the effects of the Champ4Life programme on body composition and other health-related outcomes in former elite athletes with overweight or obesity. Methods Ninety-four former athletes(42.4±7.3 y, 34.0% female) were recruited and randomly assigned to either an intervention group (IG; n=49) or a control group (CG; n=45). The IG attended 12 educational sessions addressing physical activity, weight management and nutrition. They also had a nutrition appointment aimed to prescribe a moderate caloric deficit(~300–500 kcal/day). Dual-energy X-ray absorptiometry was used to assess body composition. The Short-Form Health Survey-36 questionnaire was used to measure general health-related quality of life. Blood samples were collected to assess cardiometabolic health parameters. Results At 12 months, the IG lost more weight (estimated difference (ED)=−5.3 kg; −6.9 to −3.8), total FM (ED=−4.1 kg; −5.4 to −2.8) and abdominal FM (ED=−0.49 kg; −0.64 to −0.33) than did the CG (p’s&lt;0.001). Cardiometabolic health markers also improved significantly (p&lt;0.05) more in the IG at 12 months (insulin (ED=−4.9 μU/mL;−8.0 to −1.8); homoeostatic model assessment (ED=−1.2; −2.1 to −0.4); total cholesterol (ED=−21.8 mg/dL; -35.4 to −8.2); low-density lipoprotein (ED=18.2 mg/dL;−29.2 to −7.1)), as did quality-of-life dimensions (physical functioning (ED=11.7; 6.5 to 16.9); physical role (ED=17.6; 2.1 to 33.0); general health (ED=19.4; 11.4 to 27.4); vitality (ED=13.3; 5.3 to 21.3) and mental health (ED=12.3; 4.1 to 20.6)). Conclusions The Champ4Life programme was effective in substantially reducing total and abdominal FM while preserving fat-free mass and improving health-related markers. These findings will enable evidence-based decisions when implementing lifestyle interventions targeting retired elite athletes. Trial registeration number NCT03031951 .
1208P Final results of APOLLO study: Overall survival (OS) of aumolertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)
Authors: S. Lu, Q. Wang, G. Zhang, X. Dong, C-T. Yang, Y. Song, G-C. Chang, Y. Lu, H. Pan, C-H. Chiu, Z. Wang, J. Feng, J. Zhou, X. Xu, R. Guo, J. Chen, H. Yang, Y. Chen, Z. Yu, H-S. Shiah
Journal: Annals of Oncology (2021)
770P Wild-type BRCA1/2 ovarian cancer: Prospective follow-up data from a multidisciplinary program
Authors: I.C. Oliveira, P. Antunes Meireles, C. Pereira, P. Rodrigues, T. Duarte, S. Santos, B. Mira, A. Opinião, A.C. Luís, I. Miguel, S. Fragoso, F. Vaz
Journal: Annals of Oncology (2021)
378TiP A phase I/II/IIb study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus standard temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma
Authors: T. Weiss, T. Hemmerle, P. Roth, D. Neri, M. Weller
Journal: Annals of Oncology (2021)
1171MO PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Authors: N. Girard, H.J.M. Smit, A. Sibille, F. McDonald, F. Mornex, M.C.C. Garassino, A.R. Filippi, S. Peters, J.K. Field, D.C. Christoph, R. Fietkau, V.D. Haakensen, J. Bar, C. Chouaid, V. Bray, S. Kao, W. Sawyer, A. Allen, M. Licour, P. Garrido
Journal: Annals of Oncology (2021)
Improved breast cancer histological grading using deep learning
Authors: Y. Wang, B. Acs, S. Robertson, B. Liu, L. Solorzano, C. Wählby, J. Hartman, M. Rantalainen
Journal: Annals of Oncology (2021)

The Nottingham histological grade (NHG) is a well-established prognostic factor for breast cancer that is broadly used in clinical decision making. However, ∼50% of patients are classified as grade 2, an intermediate risk group with low clinical value. To improve risk stratification of NHG 2 breast cancer patients, we developed and validated a novel histological grade model (DeepGrade) based on digital whole-slide histopathology images (WSIs) and deep learning.In this observational retrospective study, routine WSIs stained with haematoxylin and eosin from 1567 patients were utilised for model optimisation and validation. Model generalisability was further evaluated in an external test set with 1262 patients. NHG 2 cases were stratified into two groups, DG2-high and DG2-low, and the prognostic value was assessed. The main outcome was recurrence-free survival.DeepGrade provides independent prognostic information for stratification of NHG 2 cases in the internal test set, where DG2-high showed an increased risk for recurrence (hazard ratio [HR] 2.94, 95% confidence interval [CI] 1.24-6.97, P = 0.015) compared with the DG2-low group after adjusting for established risk factors (independent test data). DG2-low also shared phenotypic similarities with NHG 1, and DG2-high with NHG 3, suggesting that the model identifies morphological patterns in NHG 2 that are associated with more aggressive tumours. The prognostic value of DeepGrade was further assessed in the external test set, confirming an increased risk for recurrence in DG2-high (HR 1.91, 95% CI 1.11-3.29, P = 0.019).The proposed model-based stratification of patients with NHG 2 tumours is prognostic and adds clinically relevant information over routine histological grading. The methodology offers a cost-effective alternative to molecular profiling to extract information relevant for clinical decisions.
826O Copanlisib plus rituximab vs placebo plus rituximab in patients (pts) with relapsed marginal zone lymphoma (MZL) treated in the phase III CHRONOS-3 trial
Authors: M. Özcan, J. Jin, Á. Szomor, P. Panayiotidis, D.H. Yoon, A.M. Tyczynska, L. Mongay Soler, A. Cao, F. Hiemeyer, B.H. Childs, M.J. Matasar, P.L. Zinzani
Journal: Annals of Oncology (2021)
863MO Nomogram for predicting survival for patients receiving definitive chemoradiation in locally advanced squamous cell carcinoma of the head and neck: A secondary analysis of NRG/RTOG 0129, 0522, and 1016
Authors: M.Z. Kharouta, N. Patil, P. Torres-Saavedra, G-M. Wang, N. Damico, A. Deshane, K. Waite, J. Dorth, M. Yao, M. Machtay, J.S. Barnholtz-Sloan, D.I. Rosenthal, N. Dunlap, J. Caudell, C.U. Jones, J.A. Ridge, P.F. Nguyen-Tan, W.A. Stokes, C. Henson, A. Bhatt
Journal: Annals of Oncology (2021)
324P Cardiovascular disease (CVD) and health care utilization (HCU) in patients (pts) with HR+, HER2 negative (HER2-) advanced breast cancer (ABC) on endocrine therapy with or without CDK4/6 inhibitor (CDK4/6i): A retrospective cohort study
Authors: S. Dent, L. Alder, G. Broadwater, T. Hyslop, K. Oeffinger, M. Khouri, S. Balu, G. Kimmick
Journal: Annals of Oncology (2021)